实体器官移植术后卡波西肉瘤研究进展  

Research progress on Kaposi sarcoma after solid organ transplantation

作　　者：方翊灵 苗芸[1] Fang Yiling;Miao Yun(Department of Organ Transplantation,Nanfang Hospital of Southern Medical University,Guangzhou 510515,China)

机构地区：[1]南方医科大学南方医院器官移植科,广州510515

出　　处：《器官移植》2025年第1期169-173,共5页Organ Transplantation

基　　金：国家自然科学基金(82270784)。

摘　　要：卡波西肉瘤是一种由人类疱疹病毒8型(HHV-8)潜伏感染并在宿主免疫抑制状态下再激活引起的内皮细胞来源恶性肿瘤。实体器官移植受者是卡波西肉瘤的高危人群,且相较于非器官移植受者,移植后卡波西肉瘤往往更具有侵袭性,内脏受累更为普遍。然而,由于移植后卡波西肉瘤相对罕见,目前尚未常规开展移植前供受者HHV-8血清抗体筛查和移植后高危人群预防,亦缺乏移植后卡波西肉瘤的诊治经验。本文就近年来实体器官移植受者卡波西肉瘤的流行病学、临床表现、发病机制和诊治经验做一综述,旨在引起移植医师的重视,并为该疾病的诊疗提供参考。Kaposi sarcoma is an endothelial cell-derived malignant tumor caused by latent infection with human herpesvirus 8(HHV-8)and reactivation under host immunosuppression.Solid organ transplant recipients are a high-risk group for Kaposi sarcoma.Compared with non-organ transplant recipients,post-transplant Kaposi sarcoma is often more aggressive and visceral involvement is more common.However,due to the relative rarity of Kaposi sarcoma after transplantation,routine pre-transplant serological screening for HHV-8 antibodies in donors and recipients and posttransplant prophylaxis for high-risk groups have not yet been carried out.And there is a lack of experience in the diagnosis and treatment of post-transplant Kaposi sarcoma.This article reviews the epidemiology,clinical manifestations,pathogenesis,diagnosis and treatment experience of Kaposi sarcoma in solid organ transplant recipients in recent years,aiming to attract the attention of transplant physicians and provide a reference for the diagnosis and treatment of this disease.

关 键 词：卡波西肉瘤 实体器官移植 人类疱疹病毒8型 卡波西肉瘤相关疱疹病毒 潜伏期相关核抗原 哺乳动物雷帕霉素靶蛋白抑制剂 紫杉醇 多柔比星 

分 类 号：R617[医药卫生—外科学] R373[医药卫生—临床医学]